Artificial intelligence (AI) already is making a difference in healthcare by helping medical professionals interpret tests, clarify diagnoses and identify…
Browsing: Hot headlines in GI
A next-generation, multitarget stool DNA test, known as the next-generation Cologuard, has demonstrated a 94% sensitivity and 91% specificity in…
Motus GI Holdings, Inc., a medical technology company focused on enhancing endoscopic outcomes, has announced that it has secured clearance…
Benjamin Levy III, MD, a gastroenterologist at University of Chicago Medicine, spoke with Becker’s to discuss how decreased reimbursements are a threat…
Mahana Therapeutics, a prominent provider of prescription digital therapeutics, unveiled significant results from an analysis presented by Dr. Mythili Pathipati…
VolitionRX Limited, an international epigenetics company, has introduced a groundbreaking cancer detection method at ESMO 2023, the European Society for…
VANCOUVER—The incidence, prevalence and mortality associated with colorectal cancer all declined in the United States from 1990 to 2019, but…
Alexandra Kharazi, MD, a cardiothoracic surgeon in California, transitioned from being an employed physician to private practice. She values the…
Two multitarget stool tests currently in development show promise for colorectal cancer (CRC) screening in average-risk individuals, as indicated by…
A study presented at UEG Week revealed that a computer-aided polyp detection system did not significantly improve adenoma or polyp…